Published in J Neurol on September 01, 2014
Consensus Paper: Cerebellar Development. Cerebellum (2016) 0.89
A variant of Nesprin1 giant devoid of KASH domain underlies the molecular etiology of autosomal recessive cerebellar ataxia type I. Neurobiol Dis (2015) 0.83
Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia. Open Biol (2015) 0.82
Disruptive SCYL1 Mutations Underlie a Syndrome Characterized by Recurrent Episodes of Liver Failure, Peripheral Neuropathy, Cerebellar Atrophy, and Ataxia. Am J Hum Genet (2015) 0.76
Identifying Niemann-Pick type C in early-onset ataxia: two quick clinical screening tools. J Neurol (2016) 0.75
Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives. Behav Neurol (2016) 0.75
Pure Cerebellar Ataxia with Homozygous Mutations in the PNPLA6 Gene. Cerebellum (2017) 0.75
A SINE Insertion in ATP1B2 in Belgian Shepherd Dogs Affected by Spongy Degeneration with Cerebellar Ataxia (SDCA2). G3 (Bethesda) (2017) 0.75
Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol (2008) 3.49
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology (2004) 3.43
Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab (2012) 3.19
Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain (2006) 3.16
Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol (2010) 2.80
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol (2007) 2.24
Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet (2005) 2.23
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology (2011) 2.09
Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain (2013) 1.95
Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol (2013) 1.82
Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol (2012) 1.77
Movement disorders in spinocerebellar ataxias. Mov Disord (2011) 1.72
Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF" mutation. Neurology (2013) 1.55
FXTAS: new insights and the need for revised diagnostic criteria. Neurology (2012) 1.39
Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis (2013) 1.38
Recent advances in the genetics of cerebellar ataxias. Curr Neurol Neurosci Rep (2012) 1.37
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy. Mitochondrion (2010) 1.24
Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3. J Neurol Neurosurg Psychiatry (2011) 1.19
Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain (2010) 1.14
Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis (2013) 1.13
The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender? J Neurol (2013) 1.09
Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord (2013) 1.05
POLG1-related and other "mitochondrial Parkinsonisms": an overview. J Mol Neurosci (2011) 1.05
The inherited ataxias: genetic heterogeneity, mutation databases, and future directions in research and clinical diagnostics. Hum Mutat (2012) 0.99
SYNE1 mutations in autosomal recessive cerebellar ataxia. JAMA Neurol (2013) 0.97
Consensus paper: management of degenerative cerebellar disorders. Cerebellum (2014) 0.95
Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. JAMA Neurol (2013) 0.95
Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol (2007) 0.92
EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias. Eur J Neurol (2009) 0.91
Differences between spinocerebellar ataxias and multiple system atrophy-cerebellar type on proton magnetic resonance spectroscopy. PLoS One (2012) 0.88
An overview of the patient with ataxia. J Neurol (2005) 0.88
Spinocerebellar ataxia: a rational approach to aetiological diagnosis. Cerebellum (2012) 0.87
Clinical and brain MR imaging features focusing on the brain stem and cerebellum in patients with myoclonic epilepsy with ragged-red fibers due to mitochondrial A8344G mutation. AJNR Am J Neuroradiol (2007) 0.85
Ocular motor characteristics of different subtypes of spinocerebellar ataxia: distinguishing features. Mov Disord (2013) 0.84
Myoclonus in mitochondrial disorders. Mov Disord (2014) 0.82
A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Pract Neurol (2012) 0.82
Levetiracetam-responsive myoclonus in spinocerebellar ataxia type 15. Mov Disord (2013) 0.81
Hereditary spastic paraparesis in adults. A clinical and genetic perspective from Tuscany. Clin Neurol Neurosurg (2014) 0.81
POLG, but not PEO1, is a frequent cause of cerebellar ataxia in Central Europe. Mov Disord (2010) 0.80
Niemann-Pick type C: a potentially treatable disorder? Pract Neurol (2013) 0.78
The wobbly child: an approach to inherited ataxias. Semin Pediatr Neurol (2008) 0.77
Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging (2005) 4.88
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch Neurol (1995) 2.30
Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. J Clin Endocrinol Metab (1997) 2.04
Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol (2004) 1.80
Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull (2003) 1.76
Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J Am Coll Cardiol (1989) 1.76
IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology (2003) 1.60
Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology (2002) 1.51
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology (2008) 1.50
White matter MRI hyperintensities in a hundred and twenty-nine consecutive migraine patients. Cephalalgia (1994) 1.49
An atypical presentation of sporadic adult-onset centronuclear myopathy. Clin Neuropathol (2007) 1.39
Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord (2003) 1.33
REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study. Neurol Sci (2005) 1.30
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology (1999) 1.25
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry (2004) 1.20
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry (2012) 1.20
Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry (2008) 1.19
TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol (2009) 1.18
EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol (2010) 1.13
Psychiatric comorbidity and psychosocial stress in patients with tension-type headache from headache centers in Italy. The Italian Collaborative Group for the Study of Psychopathological Factors in Primary Headaches. Cephalalgia (1999) 1.13
Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol (2011) 1.11
Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology (2000) 1.11
Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat (2004) 1.10
Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord (2000) 1.09
The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology (2005) 1.07
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord (2001) 1.05
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord (2001) 1.03
Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain (2004) 1.02
Astrocyte-neuron interactions in neurological disorders. J Biol Phys (2009) 1.01
Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families. J Neurol (1999) 1.00
Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables. J Neurol Neurosurg Psychiatry (2009) 0.99
CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Res Bull (2008) 0.99
Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol (1999) 0.99
Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand (2007) 0.98
Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients. Neurol Sci (2001) 0.97
Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer disease patients. Cytogenet Cell Genet (1999) 0.97
SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol (2001) 0.96
From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. Acta Neurol Scand (2005) 0.96
Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci (2001) 0.96
The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism Relat Disord (2012) 0.96
Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. Acta Paediatr (1992) 0.93
Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci (2000) 0.93
Clinical diagnosis of multiple system atrophy: level of agreement between Quinn's criteria and the consensus conference guidelines. Acta Neurol Scand (2001) 0.92
Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first? Curr Alzheimer Res (2008) 0.92
A novel mitochondrial tRNAPhe mutation causes MERRF syndrome. Neurology (2004) 0.92
A case of sarcoidosis presenting as a non-specific intramedullary lesion. Eur J Neurol (2007) 0.92
Acute and chronic effects of clozapine in essential tremor. Mov Disord (1999) 0.92
Low prevalence of TT virus in the cerebrospinal fluid of viremic patients with central nervous system disorders. J Med Virol (2001) 0.91
Improvement of motor function in early Parkinson disease by safinamide. Neurology (2004) 0.91
Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets (2010) 0.91
Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany. Neurol Sci (2007) 0.91
Clinical outcome and magnetic resonance imaging of carbon monoxide intoxication. A long-term follow-up study. Ital J Neurol Sci (1999) 0.91
Progressive sensorineural hearing loss in childhood. Pediatr Neurol (1999) 0.91
Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer's disease. Hum Genet (1997) 0.90
Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets (2009) 0.90
Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem (2011) 0.89
Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging (2005) 0.89
Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin Genet (2011) 0.89
Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma. Mov Disord (2000) 0.89
Mitochondria, cognitive impairment, and Alzheimer's disease. Int J Alzheimers Dis (2009) 0.89
Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur J Neurol (2009) 0.89
Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. J Neurol Neurosurg Psychiatry (2001) 0.88
Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol (2008) 0.88
Charcot-Marie-Tooth disease type I and related demyelinating neuropathies: Mutation analysis in a large cohort of Italian families. Hum Mutat (2001) 0.88
Prognostic factors in mild dystrophinopathies. J Neurol Sci (1996) 0.88
A whole-brain analysis in de novo Parkinson disease. AJNR Am J Neuroradiol (2008) 0.88
The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr Alzheimer Res (2009) 0.88
The clinical spectrum of sarcoglycanopathies. Neurology (1999) 0.88
Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. Parkinsonism Relat Disord (2004) 0.87
Novel sarcoglycan gene mutations in a large cohort of Italian patients. J Med Genet (2003) 0.87
Muscle modifications in Parkinson's disease: myoelectric manifestations. Electroencephalogr Clin Neurophysiol (1996) 0.87
Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm (Vienna) (2004) 0.86
Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports. Ital J Neurol Sci (1983) 0.86
Diagnostic approach to mitochondrial disorders: the need for a reliable biomarker. Curr Mol Med (2009) 0.86
Nature of motions between sarcomeres in asynchronously contracting cardiac muscle cells. Biophys J (1992) 0.86
Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci (2002) 0.86
Myopathic involvement in two cases of Hallervorden-Spatz disease. Brain Dev (1996) 0.85
Magnetization transfer imaging demonstrates a distributed pattern of microstructural changes of the cerebral cortex in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol (2011) 0.85
DPP6 gene variability confers increased risk of developing sporadic amyotrophic lateral sclerosis in Italian patients. J Neurol Neurosurg Psychiatry (2008) 0.85
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J Neural Transm (Vienna) (2006) 0.85
A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology (1995) 0.84
Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol (1992) 0.84
Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol (2010) 0.84
Headache, panic disorder and depression: comorbidity or a spectrum? Neuropsychobiology (1995) 0.84
Mitochondrial tRNA(Cys) gene mutation (A5814G): a second family with mitochondrial encephalopathy. Neuromuscul Disord (1997) 0.84
Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol (1997) 0.84
Phenobarbital prophylaxis of post traumatic epilepsy. Ital J Neurol Sci (1980) 0.84
Molecular characterization of myophosphorylase deficiency in a group of patients from northern Italy. J Neurol Sci (1996) 0.84
Limbic encephalitis associated with thymic cancer: a case report. J Neurol (2001) 0.83
Trigemino-cervical reflex in pathology of the brain stem and of the first cervical cord segments. Electromyogr Clin Neurophysiol (1989) 0.83
Metabolic myopathies: functional evaluation by different exercise testing approaches. Musculoskelet Surg (2011) 0.83